| Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial MP Manns, JG McHutchison, SC Gordon, VK Rustgi, M Shiffman, ... The Lancet 358 (9286), 958-965, 2001 | 8349 | 2001 |
| Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C JG McHutchison, SC Gordon, ER Schiff, ML Shiffman, WM Lee, VK Rustgi, ... New England Journal of Medicine 339 (21), 1485-1492, 1998 | 4576 | 1998 |
| Sofosbuvir for previously untreated chronic hepatitis C infection E Lawitz, A Mangia, D Wyles, M Rodriguez-Torres, T Hassanein, ... New England Journal of Medicine 368 (20), 1878-1887, 2013 | 2449 | 2013 |
| Boceprevir for previously treated chronic HCV genotype 1 infection BR Bacon, SC Gordon, E Lawitz, P Marcellin, JM Vierling, S Zeuzem, ... New England Journal of Medicine 364 (13), 1207-1217, 2011 | 2247 | 2011 |
| Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection N Afdhal, KR Reddy, DR Nelson, E Lawitz, SC Gordon, E Schiff, ... New England Journal of Medicine 370 (16), 1483-1493, 2014 | 1722 | 2014 |
| Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C GL Davis, R Esteban-Mur, V Rustgi, J Hoefs, SC Gordon, C Trepo, ... New England journal of medicine 339 (21), 1493-1499, 1998 | 1595 | 1998 |
| Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis KV Kowdley, SC Gordon, KR Reddy, L Rossaro, DE Bernstein, E Lawitz, ... New England Journal of Medicine 370 (20), 1879-1888, 2014 | 1519 | 2014 |
| Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options IM Jacobson, SC Gordon, KV Kowdley, EM Yoshida, M Rodriguez-Torres, ... New England journal of medicine 368 (20), 1867-1877, 2013 | 1439 | 2013 |
| Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection JG McHutchison, GT Everson, SC Gordon, IM Jacobson, M Sulkowski, ... New England Journal of Medicine 360 (18), 1827-1838, 2009 | 1432 | 2009 |
| Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial ZM Younossi, V Ratziu, R Loomba, M Rinella, QM Anstee, Z Goodman, ... The Lancet 394 (10215), 2184-2196, 2019 | 1165 | 2019 |
| Elafibranor, an agonist of the peroxisome proliferator− activated receptor− α and− δ, induces resolution of nonalcoholic steatohepatitis without fibrosis worsening V Ratziu, SA Harrison, S Francque, P Bedossa, P Lehert, L Serfaty, ... Gastroenterology 150 (5), 1147-1159. e5, 2016 | 1165 | 2016 |
| Sofosbuvir and velpatasvir for HCV genotype 2 and 3 infection GR Foster, N Afdhal, SK Roberts, N Bräu, EJ Gane, S Pianko, E Lawitz, ... New England Journal of Medicine 373 (27), 2608-2617, 2015 | 1070 | 2015 |
| A randomized, double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C KL Lindsay, C Trepo, T Heintges, ML Shiffman, SC Gordon, JC Hoefs, ... Hepatology 34 (2), 395-403, 2001 | 960 | 2001 |
| Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection … PY Kwo, EJ Lawitz, J McCone, ER Schiff, JM Vierling, D Pound, MN Davis, ... The Lancet 376 (9742), 705-716, 2010 | 858 | 2010 |
| Efficacy of obeticholic acid in patients with primary biliary cirrhosis and inadequate response to ursodeoxycholic acid GM Hirschfield, A Mason, V Luketic, K Lindor, SC Gordon, M Mayo, ... Gastroenterology 148 (4), 751-761. e8, 2015 | 699 | 2015 |
| Sofosbuvir, velpatasvir, and voxilaprevir for previously treated HCV infection M Bourlière, SC Gordon, SL Flamm, CL Cooper, A Ramji, M Tong, ... New England Journal of Medicine 376 (22), 2134-2146, 2017 | 678 | 2017 |
| Primary biliary cirrhosis in monozygotic and dizygotic twins: genetics, epigenetics, and environment C Selmi, MJ Mayo, N Bach, H Ishibashi, P Invernizzi, RG Gish, SC Gordon, ... Gastroenterology 127 (2), 485-492, 2004 | 590 | 2004 |
| Eltrombopag for thrombocytopenia in patients with cirrhosis associated with hepatitis C JG McHutchison, G Dusheiko, ML Shiffman, M Rodriguez-Torres, S Sigal, ... New England Journal of Medicine 357 (22), 2227-2236, 2007 | 573 | 2007 |
| Evaluation of a panel of non-invasive serum markers to differentiate mild from moderate-to-advanced liver fibrosis in chronic hepatitis C patients K Patel, SC Gordon, I Jacobson, C Hézode, E Oh, KM Smith, ... Journal of hepatology 41 (6), 935-942, 2004 | 501 | 2004 |
| Treatment of unresectable hepatocellular carcinoma with use of 90Y microspheres (TheraSphere): safety, tumor response, and survival R Salem, RJ Lewandowski, B Atassi, SC Gordon, VL Gates, O Barakat, ... Journal of vascular and interventional radiology 16 (12), 1627-1639, 2005 | 471 | 2005 |
